Cystic Fibrosis Trust responds to O'Shaughnessy's review of clinical trials landscape

Dr Lucy Allen, Director of Research and Healthcare data at Cystic Fibrosis Trust, said: "Clinical trials are vital in enhancing development of new treatments, particularly for people with life-long conditions like cystic fibrosis (CF) and we're pleased to see our work inspiring the recommendations in this review. We're committed to increasing participation and improving the quality and success of new clinical trials in CF. Since our UK CF Clinical Trials Accelerator Platform (CTAP) launched, we've supported over 50 studies, and enabled over 2000 people with cystic fibrosis to take part in a trial. These trials are vital to realising our vision of a life unlimited by cystic fibrosis. And we hope that with Lord O’Shaughnessy’s recommendations and the Government's backing, the UK will continue to be a global leader in this area."